OSI-774-206, Open-label, Phase 2 Study of Single-agent E

Project: Research project

Project Details

Description

OSI-774-206, Open-label, Phase 2 Study of Single-agent Erlotinib for Patients with Pediatric Ependymoma Previously Treated with Oral Etoposide in Protocol OSI-774-205
StatusFinished
Effective start/end date1/1/1112/31/12

Funding

  • OSI Pharmaceuticals, Inc.

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.